Theraclone Announces Exclusive Agreement with Gilead Sciences for Broadly Neutralizing HIV Antibodies

July 30th, 2014 Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today that it has entered into an agreement with Gilead Sciences, Inc., under which Gilead received an exclusive license to develop and commercialize products incorporating Theraclone’s broadly neutralizing HIV-antibodies for therapeutic applications in HIV. These broadly neutralizing antibodies (bNAbs) were discovered in collaboration with the International …